In the first phase, it mainly explores the safety, tolerability and preliminary effectiveness
of two doses of OH2 injection in the treatment of patients with recurrent central nervous
system tumors; to evaluate the biodistribution and virus shedding of OH2 injection
administered in the tumor cavity; to evaluate the level of anti-HSV2 antibody in patients
when OH2 injection is administered intracavitary to tumor; to determine the phase II
recommended dose (RP2D) of OH2 injection in the treatment of recurrent glioblastoma.
Phase IIa, to evaluate the preliminary efficacy of OH2 injection in the treatment of patients
with recurrent glioblastoma after surgery, and to further evaluate the safety of OH2 in the
treatment of relapsed glioblastoma.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.